Delivery Order SPE2DR25D1053-SPE2DR26FV406
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,023.47 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 21, 2025, and was competitively awarded without set-aside provisions. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $2,425.07 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply). This competitively awarded, firm fixed-price delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025, and represents a non-set-aside procurement. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,736.12 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets in quantities of 30 units. This competitive award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $6,047.25 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This competitive award, issued on June 20, 2025, with an ultimate completion date of June 23, 2025, represents a firm fixed price delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $1,962.99 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) with a ceiling value of $12,956.50 under a firm fixed price contract type. The award was made on October 21, 2025, with an ultimate completion date of October 22, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $5,724.72 delivery order to AmerisourceBergen Drug Corp on January 6, 2026, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This firm fixed-price delivery order, which is set to be completed by January 7, 2026, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to compete on a full...
- The Defense Logistics Agency awarded a $8,353.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30 count) with an ultimate completion date of December 22, 2025. This non-set-aside, firm fixed-price delivery order was competitively awarded and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is located in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,097.78 for Ondansetron ODT 4 mg tablets (30-count supply) on November 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating it was competitively awarded. Performance is scheduled for completion by December 1, 2025, and work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,663.17 to Amerisourcebergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count package). The award, issued on January 8, 2026, is structured as a firm fixed-price contract with an ultimate completion date of January 9, 2026, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This contract was not designated as a set-aside and was competitively awarded, reflecting...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FV406Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $31,740.85 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages). This competitively awarded, firm fixed-price delivery order was issued on January 9, 2026, with an ultimate completion date of January 12, 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside contract, this award reflects open competition in the federal pharmaceutical procurement marketplace. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s large Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the supply of brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare programs worldwide. Ondansetron is a critical anti-nausea medication widely used in military treatment facilities and veteran healthcare programs, positioning this delivery order within the broader context of DLA's essential pharmaceutical supply chain for the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.7k | 1/8/26 |